(Q45115319)

9 December 2017

0 references

Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis (English)

1 reference

9 December 2017

Hao Jiang

1

1 reference

9 December 2017

Wei Zhao

series ordinal

2

1 reference

9 December 2017

Wei Shao

series ordinal

3

1 reference

9 December 2017

publication date

7 June 2014

1 reference

9 December 2017

1 reference

9 December 2017

volume

35

1 reference

9 December 2017

issue

8

1 reference

9 December 2017

page(s)

7383-7389

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-014-2150-3

9 December 2017

exact match

0 references

cites work

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Guidelines on treatment of stage IIIB non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Epidemiology of Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

CD44 variant isoforms in head and neck squamous cell carcinoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

CD44 in cancer progression: adhesion, migration and growth regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Prognostic significance of CD44 expression in adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Prognostic significance of CD44s expression in resected non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

CD44: structure, function, and association with the malignant process.

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

21 January 2018

12 December 2020

Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2150-3

Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection

21 January 2018

1 reference

12 December 2020

Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor

1 reference

12 December 2020

Role of VEGF and CD44v6 in differentiating benign from malignant ascites

1 reference

12 December 2020

Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases

1 reference

12 December 2020

Expression of human CD44v6 in non-small-cell lung cancer

1 reference

12 December 2020

Expression and prognostic value of the standard CD44 protein in pulmonary adenocarcinoma

1 reference

12 December 2020

CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance

1 reference

12 December 2020

MMP-2, TIMP-2 and CD44v6 expression in non-small-cell lung carcinomas

1 reference

12 December 2020

CD44 variant exon 6 expressions in colon cancer assessed by quantitative analysis using real time reverse transcriptase-polymerase chain reaction

1 reference

12 December 2020

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

1 reference

12 December 2020

Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma

1 reference

12 December 2020

Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas.

1 reference

12 December 2020

Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma

1 reference

12 December 2020

10.1007/S13277-014-2150-3

Identifiers

DOI

1 reference

Dimensions Publication ID

9 December 2017

1052322220

0 references

1 reference